These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3115339)

  • 1. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma.
    Kurzrock R; Talpaz M; Kantarjian H; Walters R; Saks S; Trujillo JM; Gutterman JU
    Blood; 1987 Oct; 70(4):943-7. PubMed ID: 3115339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.
    Alimena G; Morra E; Lazzarino M; Liberati AM; Montefusco E; Inverardi D; Bernasconi P; Mancini M; Donti E; Grignani F
    Blood; 1988 Aug; 72(2):642-7. PubMed ID: 3165298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
    Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-alpha correlates with the degree of receptor down-regulation.
    Bartsch HH; Pfizenmaier K; Hanusch A; Scheurich P; Ucer U; Nagel GA
    Int J Cancer; 1989 Feb; 43(2):235-40. PubMed ID: 2521842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma.
    Herrmann F; Jonas D; Helfrich SG; Lindemann A; Schleiermacher E; Mertelsmann R
    Blut; 1990 Oct; 61(4):226-31. PubMed ID: 2121299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
    Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M
    Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Ph+ chronic myeloid leukemia by gamma interferon.
    Russo D; Fanin R; Zuffa E; Gallizia C; Grazia Michieli M; Damiani D; Testoni N; Pecile V; Visani G; Colombini R
    Blut; 1989 Jul; 59(1):15-20. PubMed ID: 2502210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM).
    Carlo-Stella C; Cazzola M; Ganser A; Bergamaschi G; Pedrazzoli P; Hoelzer D; Ascari E
    Blood; 1988 Oct; 72(4):1293-9. PubMed ID: 3139105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
    Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
    Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
    Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors.
    McGlave P; Mamus S; Vilen B; Dewald G
    Exp Hematol; 1987 May; 15(4):331-5. PubMed ID: 3106077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients.
    Kurzrock R; Feinberg B; Talpaz M; Saks S; Gutterman JU
    J Interferon Res; 1989 Aug; 9(4):435-44. PubMed ID: 2502584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia.
    Wandl UB; Kloke O; Nagel-Hiemke M; Moritz T; Becher R; Opalka B; Holtkamp W; Bartels H; Seeber S; Niederle N
    Br J Haematol; 1992 Aug; 81(4):516-9. PubMed ID: 1390238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia.
    Kloke O; Becher R; Niederle N
    Blut; 1987 Nov; 55(5):453-8. PubMed ID: 3118992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
    Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
    Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating MJ; Talpaz M
    Leukemia; 1997 Oct; 11(10):1610-6. PubMed ID: 9324278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.
    Aulitzky WE; Peschel C; Desprès D; Aman J; Trautman P; Tilg H; Rudolf G; Hüttmann H; Obermeier J; Herold M
    Ann Hematol; 1993 Nov; 67(5):205-11. PubMed ID: 7694661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.